Bioventus Inc. (NYSE:BVS) SVP Sells $44,632.20 in Stock

Bioventus Inc. (NYSE:BVS) SVP Anthony D’adamio sold 4,380 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total transaction of $44,632.20. Following the completion of the transaction, the senior vice president now directly owns 118,178 shares of the company’s stock, valued at $1,204,233.82. The trade was a 3.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Bioventus Stock Up 0.6 %

Shares of NYSE:BVS opened at $10.01 on Friday. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. The firm has a market cap of $812.31 million, a price-to-earnings ratio of -16.41 and a beta of 0.85. The stock’s 50-day moving average price is $10.32 and its two-hundred day moving average price is $10.86. Bioventus Inc. has a 12-month low of $3.90 and a 12-month high of $14.38.

Institutional Investors Weigh In On Bioventus

Hedge funds have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. increased its position in Bioventus by 38.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 390,162 shares of the company’s stock worth $4,662,000 after purchasing an additional 109,359 shares during the last quarter. Segall Bryant & Hamill LLC purchased a new stake in shares of Bioventus during the 3rd quarter valued at $4,515,000. Point72 Asset Management L.P. acquired a new stake in shares of Bioventus during the 3rd quarter worth $788,000. JPMorgan Chase & Co. raised its position in shares of Bioventus by 228.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 253,740 shares of the company’s stock worth $3,032,000 after buying an additional 176,442 shares during the period. Finally, State Street Corp boosted its holdings in Bioventus by 38.8% in the third quarter. State Street Corp now owns 676,501 shares of the company’s stock valued at $8,084,000 after acquiring an additional 189,216 shares during the last quarter. 62.94% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on BVS. JPMorgan Chase & Co. raised shares of Bioventus from an “underweight” rating to a “neutral” rating and boosted their price objective for the company from $12.00 to $13.00 in a research report on Tuesday, December 17th. Canaccord Genuity Group lifted their target price on shares of Bioventus from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.